Introduction
Bangladesh has a history of endemic malaria transmission in 13 of 64 districts. Up to 70 000 laboratory-confi rmed and 900 000 clinical cases (appendix p 1), with more than 500 deaths per year, were reported in the late 1990s. [1] [2] [3] Unreported cases might have been as high as 250 000 each year. 4 A cross-sectional survey in 2007 reported a crude prevalence of 4% in the 13 malaria-endemic districts. 5 More than 90% of cases were Plasmodium falciparum. 5 The highest prevalence (>10%) was identifi ed in three districts of the Chittagong Hill Tracts in southeastern Bangladesh. 5 The Global Fund to fi ght AIDS, Tuberculosis and Malaria (Global Fund) approved funds in 2006 4 (Round 6) and 2009 6 (Round 9) to support the Bangladesh National Malaria Control Program (NMCP). The NMCP was implemented by the Bangladesh Ministry of Health with BRAC (a national non-governmental development organisation). The goals were to: (1) reduce malaria morbidity and mortality; (2) provide community-based services that increased access to diagnosis and treatment with artemisinin-based combination therapies in hard-toreach regions; (3) provide longlasting insecticidal nets (LLINs) to 100% of households in the three malariaendemic districts with the highest malaria burden and 80% coverage in the other ten malaria-endemic districts; (4) strengthen the malaria epidemiological surveillance system; (5) strengthen partnerships in malaria control; and (6) provide periodic (every 3 years) treatment of non-LLIN with suitable insecticides. 4, 6 These interventions started in late 2007, and were fully implemented in the 13 malaria-endemic districts in 2008 . There has been a general reduction in malaria cases, presumably through high coverage of and increased use of insecticide-treated nets, increased use of rapid diagnostic tests and antimalarial treatments, and a high number of community health workers and health facilities. [7] [8] [9] The interventions have also reached marginalised populations. 8 Bangladesh is moving from control to elimination in parts of the country, but evidence in favour of these actions has been more descriptive than quantitative so a robust cost-benefi t analysis is crucial. Cost-eff ectiveness analysis is needed to maintain sustainable control programmes and assess the future needs for malaria elimination.
Malaria elimination also has substantial indirect benefi ts and economic attractiveness. 10, 11 A systematic assessment of the eff ect of the programme has not been done in Bangladesh. Both donors and policy makers should have information about the costs and benefi ts of interventions. To address this gap, we did an epidemiological and economic analysis using the country's number of malaria episodes, total costs of the programme, and disbursed funds from 2008 to 2012 in the 13 malaria-endemic districts. We compared international donor assistance to control malaria in Bangladesh with other malaria-endemic countries.
Methods

Study area
The population of Bangladesh is about 150 million; 14 million people live in the 13 malaria-endemic districts. 12 Eight of these districts are in the north of Bangladesh, sharing a border with India, and fi ve districts are in southeast Bangladesh, sharing borders with India and Myanmar (Burma).
Data sources
The main methods of malaria surveillance in Bangladesh are passive case detection at hospitals and rapid diagnosis and treatment at the community level by community health workers. We obtained annually reported, districtlevel aggregated malaria case data from the NMCP. Uncomplicated malaria, severe malaria (defi ned by clinical and laboratory variables associated with an increased risk of death and the presence of P falciparum parasitaemia) 13, 14 involving admission to hospital, and malaria-associated mortality, were confi rmed by microscopy or rapid diagnostic tests done in hospitals or by community health workers. Appendix p 2 shows the malaria reporting system in Bangladesh in more detail. We obtained data for the number of LLINs distributed and nets treated (new available non-LLIN) with K-O-tab 123 15 (together designated as insecticide-treated nets) annually from the NMCP. LLINs were costed at $6·00 per net, and insecticide treatment of nets at $0·50 per net. We took demographic data from the Bangladesh Bureau of Statistics. 
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We obtained detailed data from the Bangladesh NMCP for funds disbursed to the NMCP from the donors (Global Fund, Bangladesh Government). Once the investments from the Global Fund arrived in Bangladesh, they were deposited in the Ministry of Health according to the US dollar rate. Infl ation rates were calculated on the basis of diff erences between the rate at the time the funds were received and the reporting time at the end of the fi scal year. We obtained cost data in US dollars from the Bangladesh NMCP manager. All costs were cross-checked with budgets outlined in the original proposals submitted to the Global Fund and through reviews of available reports.
Data analysis
We analysed yearly aggregated district-level age (0·0-4·0 years, 4·1-14·0 years, and >14·0 years) and sexspecifi c malaria data for all 13 malaria-endemic districts. We used detailed demographic data from the Bangladesh Bureau of Statistics as the denominator. We calculated the prevalence 17 of any malaria, severe malaria, and malaria-associated mortality per 1000 population. For all 13 districts, we calculated coverage of insecticide-treated nets per 1000 population, assuming an average net life of 3 years. 18 We used Poisson regression to explore the association between malaria prevalence and insecticidetreated net coverage at the district level. We used STATA (version 11) for all statistical analyses.
Yearly malaria data (total number of malaria episodes, P falciparum, Plasmodium vivax, and mixed infections) were linked with district shape fi les (geographic data). District-level malaria prevalence in each year and the percentage of P falciparum, P vivax, and mixed infections were mapped separately and analysed for spatial clustering using the Getis-Ord Gi* statistic 19 in ArcGIS software (version 10). This statistic established whether diff erences between the local mean (ie, the prevalence for a district and its nearest neighbouring districts) was signifi cantly diff erent from the global mean (ie, the prevalence for all districts). 20 A signifi cant positive Z score identifi ed a hotspot for high prevalence and a signifi cant negative Z score for a district identifi ed local clustering of low prevalence. [21] [22] [23] For the economic analyses, all costs were treated as capital costs (eg, transportation, human resources, training, infrastructures, institutional overhead, operational research), except costs for drugs, diagnoses, health education (information education communication or behaviour change communication), LLINs, and impregnation of nets to prevent malaria, which were treated as operating costs. The population (14 million people) living in malaria-endemic districts of the country was used as the denominator. For the analysis of international donor assistance to control malaria, we calculated each malaria-endemic country's total expenditures from international donors to control malaria from 2008 to 2012, and their populations living in malaria-endemic regions. We compared the total population living at risk and disbursed funds for malaria control in Bangladesh with other malariaendemic countries.
Role of the funding source
There was no funding source for this study. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
During the study period (from Jan 1, 2008, to Dec 31, 2012) there were 285 731 confi rmed malaria cases in the 13 malaria-endemic districts. There was a steep decrease in malaria from 6·2 cases per 1000 population in 2008, to 2·1 cases per 1000 population in 2012 (fi gure 1). Between 2008 and 2012, prevalence of all malaria decreased by 65% (95% CI 65-66), severe malaria decreased by 79% (78-80), and malaria-associated mortality decreased by 91% (83-95) (table). Malaria prevalence among male individuals was 1·3 times higher than in female individuals over the course of the study (table) . Malaria prevalence decreased between 2008 and 2012 in all age groups (table), but the highest decrease was in children aged 0-4 years: 77% (95% CI 76-78; appendix p 3).
From 2008 to 2012, the Bangladesh NMCP did 2·2 million diagnostic tests for malaria (71% microscopy, 29% rapid diagnostic tests). Of 285 731 tests that were positive for malaria, 56% (160 715) were confi rmed by rapid diagnostic test (Paracheck-Pf, Orchid, Biomedical System, Verna, Goa, India) 24 and 44% (125 863) were confi rmed by microscopy (appendix p 4). Treatments provided by the Bangladesh NMCP for patients with malaria were artemether-lumefantrine, chloroquine, primaquine, and quinine (appendix pp 9-11).
Most malaria cases were P falciparum (89·3%, 255 266), 10·3% (29 367) were P vivax, and 0·4% (1089) were mixed infections (P falciparum plus P vivax; appendix pp 5-7).
During the study period, 3·11 million new LLINs were supplied and an additional 3·77 million nets were treated with insecticide. 15 By 2012, there was one insecticidetreated net for every 2·6 individuals (SD 0·20) in the 13 malaria-endemic districts (fi gure 2).
The decrease in malaria prevalence in all age groups was associated with increased insecticide-treated net coverage (table) . Districts with more than 0·5 insecticidetreated nets per person had an annual decrease in prevalence of 21% for all malaria, 25% for severe malaria, and 76% for malaria-associated mortality among all age groups (table) . Coverage of more than 0·5 insecticidetreated nets per person was associated with a greater 
ITN coverage (number of nets per person)*
ITN=insecticide-treated net. *Average coverage for 2008-12. Assuming one insecticide-treated net provides cover for two individuals, the amount spent for distribution of 6·88 million insecticide-treated nets (LLINs and nonLLINs) was $0·68 (SD 0·30) per person per year during 2008-12. During the study period, the mean cost per diagnosed malaria case was $0·39 (SD 0·02) and the average cost per malaria case treated was $0·51 (0·27). Bangladesh also spent an average of $0·05 (0·04) per person yearly for health education. From 2008 to 2012, 87 malaria-endemic countries received fi nancial support from international donors to control malaria. 25, 26 In terms of size of population living at risk of malaria, of 91 endemic countries, Bangladesh (14 million people living in endemic districts) ranked 29th. 25, 26 However, Bangladesh ranked 57th in terms of amount of international funding invested ($2·04 per person; fi gure 4).
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Discussion
The prevalence of all malaria, severe malaria, and malaria-associated mortality decreased in Bangladesh after 5 years of interventions. The annual number of cases declined, especially in children aged 0-4 years. Bangladesh achieved high insecticide-treated net coverage and the extent of coverage was associated with the reduction in cases. Cost per diagnosis, 27 ,28 cost per treated case, 27 and cost of insecticide-treated net coverage 27, [29] [30] [31] [32] were lower than for malaria control programmes in other countries, suggesting that the Bangladesh NMCP is cost-eff ective.
Despite limited funds, the Bangladesh NMCP has achieved success in reducing malaria. 27, 33, 34 Increased prevention and control measures have reduced the malaria burden in Bangladesh, although some of the decreases might have been a result of external factors.
Bangladesh provided one insecticide-treated net for every 2·6 individuals in the 13 malaria-endemic districts, higher than many other malaria-endemic countries. [35] [36] [37] Results of another study in the Bandarban district showed that more than 90% of individuals slept under nets during the night before the interview. 38 Of the nets used, about 80% were reported to be insecticidetreated and more than 95% of children younger than 5 years used an insecticide-treated net. 38 Since increased insecticide-treated net coverage was associated with a reduction in malaria cases in the present study, maintenance of high coverage of insecticide-treated nets will probably be crucial in future.
For diagnosis of malaria, the proportional use of rapid diagnostic tests (29%) was much lower than that of microscopy (71%; appendix p 8). However, the proportion of confi rmed cases diagnosed by rapid diagnostic tests was higher (56%) than for microscopy (44%). This fi nding might have arisen because microscopy is mainly used in government hospitals to which most people refer for treatment but which are mainly located in urban areas where malaria-infection rates are low. Rapid diagnostic tests are mainly used by community health workers working in hard-to-reach regions in which prevalence is thought to be higher.
The lower prevalence of malaria in female individuals than male individuals might relate to the high risk of exposure in typically male occupations, such as agricultural and forestry. 4, 39 Behavioural diff erences might also play a part; for example, women are generally well covered with clothing, prefer to sleep earlier (therefore spending more time under nets), and tend to sleep with their children under nets. 4, 38, 39 After 5 years of malaria control interventions, hotspots persist in the Chittagong Hill Tracts. More intensive and targeted surveillance systems, including mapping of asymptomatic carriers, is needed. 7 Identifi cation and targeting of transmission in the Chittagong Hill Tracts and Cox's Bazar district on a regular basis will be crucial to reduce the malaria burden. 5, 8, 12, 40, 41 Currently, Bangladesh has elimination programmes (begun in 2012) in four districts in northeast Bangladesh. The programmes monitor annual malaria cases at the district level. Monthly malaria maps at the lowest administrative level (mauza) could further help control programmes to be more cost-eff ective by more accurately targeting resources.
The costs per person for diagnosis ($0·39) and treatment ($0·51) of malaria in Bangladesh were low compared with other countries (range $0·88-9·54). 27, 28, 42 Bangladesh also spent a small amount of funds on health education with a radio, leafl et, and advertisement campaign. So far, artemisinin-based combination therapies (lumefantrine-artemether, artesunate; appendix pp 9-11) are highly eff ective for treatment of malaria in Bangladesh. 43, 44 However, close monitoring of drug resistance is essential in Bangladesh because resistance to artemisinin-based combination therapies has been reported at the Thai-Cambodia border 45 and more recently at the Thai-Myanmar border. 46 Monitoring of the potential spread of resistance of artemisinin-based combination therapies should be a high priority in Bangladesh.
In addition to providing relatively expensive LLINs, the NMCP also supported cheaper insecticide treatment of nets, 15 thus Bangladesh maintained highly cost-eff ective insecticide-treated net coverage compared with other malaria-endemic countries. [29] [30] [31] [32] The average international donor support for malaria control worldwide to malaria-endemic countries was US$1·86 per person per year. 47 The corresponding fi gure for Bangladesh was $0·41 per person per year for the population living at risk of malaria, which is less than the $0·70 per person per year given to the countries in the southeast Asian and western Pacifi c regions. 47 The greatest threat to a successful elimination plan for Bangladesh is the border areas with Myanmar and Indian states of Assam, Tripura, Meghalaya, and Mizoram. [48] [49] [50] [51] [52] [53] [54] Areas adjacent the porous border are malaria endemic, largely mountainous, and composed of forest reserves. A cross-border malaria strategy with India and Myanmar is crucial to maintain the gains that have been achieved. One way could be to implement border screening and develop cross-border and regional malaria collaborations that will move Bangladesh forward in malaria elimination.
This study has a number of limitations. For example, it is known that economic development and urbanisation can be associated with reduced malaria. 55 It is, therefore, possible that not all improvements in the malaria situation were attributable to the control activities of the NMCP. Bangladesh has undergone substantial progress in terms of general societal development. This progress and improved access to health care in general could have contributed to a decrease in malaria prevalence irrespective of the activities of the NMCP. The number of malaria cases identifi ed for the present study might be underestimated if substantial numbers of people acquire antimalarial drugs from vendors that do not report to the country's malaria record. The rapid diagnostic test used by the Bangladesh NMCP (Paracheck-Pf) only detects P falciparum, leaving P vivax infections (which can be detected by microscopy) undetected. False positives or www.thelancet.com/lancetgh Vol 2 February 2014 e104 negatives with either microscopy or rapid diagnostic tests were not considered. Importation risk from India or Myanmar has not been considered and the cost calculations also did not take into account expired antimalarial drugs and rapid diagnostic tests or loss in the government stocks. Malaria control in Bangladesh is mostly donordependent. The country has been successful in securing $39·81 million from the Global Fund for its malaria programme from 2008 to 2012 and obtained a further $25 million until June, 2015, from the Global Fund. However, the Bangladesh NMCP is currently underfunded relative to the size of the population living at risk of malaria, and improved funding will be crucial for elimination eff orts. The present assessment will support future malaria control strategies by the Ministry of Health in Bangladesh and donors. A resurgence of malaria in Bangladesh is nearly assured if control and surveillance measures are scaled back before elimination has been achieved (panel). 56, 57 Consistent fi nancing, which will require a substantial change in the approach to malaria funding, is necessary to avoid resurgence. The case for elimination is already suffi ciently compelling for Bangladesh. The benefi ts are not only local, but also international if Bangladesh can act as a buff er against the spread of artemisinin resistance from the Mekong region to the Indian subcontinent. Furthermore, experiences from the fi eld in countries involved in malaria control, such as Bangladesh, will also be of importance for programme design in other malaria-endemic countries.
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Interpretation
Bangladesh is moving closer to elimination of malaria. On the basis of the reductions in malaria prevalence that we have identifi ed, malaria elimination is an achievable prospect in Bangladesh; however, resurgence of malaria is nearly assured if control and surveillance measures are scaled back. Consistent fi nancing will be needed to avoid resurgence and maintain elimination goals.
